CJC-1295
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
CJC-1295 is a re-engineered version of the working end of your own GHRH (growth-hormone-releasing hormone). Natural GHRH tells your pituitary to release a pulse of GH — but it’s destroyed within minutes by the enzyme DPP-4. CJC-1295 carries amino-acid swaps that resist that breakdown, so the “make more GH” signal lasts far longer. It comes in two forms, and the difference is the single most important thing to understand about it.
With-DAC carries a Drug Affinity Complex — an albumin-binding hook. Once injected, it latches onto albumin, the most abundant protein in your blood, and becomes effectively invisible to the enzymes and kidneys that would clear it. The result: one injection keeps working for the better part of a week. As one practitioner puts it, the peptide “circulates for over a week, up to two weeks” off a single shot.
No-DAC (also called modified GRF 1-29) skips that hook and clears in hours, so it’s dosed daily. This is the form in most blends, including Alyve’s.
Like Sermorelin, CJC-1295 works upstream — it doesn’t inject GH, it asks your pituitary to make its own, in pulses, with your natural feedback braking intact. That’s the physiologic-restoration approach one practitioner contrasts favorably against exogenous HGH.
What does it do in my body?
CJC-1295 binds the GHRH receptor on your anterior pituitary. That triggers the standard GHRH cascade — calcium influx, cyclic-AMP spike — and the pituitary releases GH. The engineering is all about durability: native GHRH is shredded by DPP-4 in minutes; CJC-1295’s modifications resist that, and the DAC variant’s albumin-binding extends circulation into days [PMID 16352683].
The most elegant finding from the human work: even with a sustained signal, GH still came out in pulses — your natural rhythm was preserved — and what actually drove IGF-1 up was the raised trough (baseline between pulses), not blown-out peaks. Your body kept its own dimmer switch (somatostatin feedback). That’s why CJC-1295 pairs so naturally with a ghrelin-receptor agonist like Ipamorelin: CJC raises the GHRH-driven baseline, ipamorelin triggers a clean pulse through a separate receptor, and the pituitary — expressing both — puts out more GH together than either alone (see CJC-1295 / Ipamorelin).
On the DAC question, one practitioner is emphatic: native GHRH dies to DPP-4 in minutes; no-DAC lasts a few hours; with-DAC binds albumin and circulates for a week-plus, giving more consistent IGF-1 and slower tachyphylaxis. He steers most users to the DAC form: “with DAC is the one I’m telling you should consider”. He cites a “2013 JCEM” paper for once-weekly with-DAC producing consistent IGF-1 — that specific cite doesn’t resolve, but the real source behind it is Teichman 2005 JCEM (the single-dose ascending-dose RCT showing sustained GH/IGF-1 over 6–11 days), corroborated by Ionescu 2006 on preserved pulsatility.
Where experts read it differently — with-DAC vs no-DAC (added 2026-06-16). Two clearly-articulated expert positions in the KB, presented honestly per umbrella §2 evidence-honesty doctrine so readers can weigh both:
- The with-DAC case (one practitioner): native GHRH dies to DPP-4 in minutes; no-DAC lasts a few hours; with-DAC binds albumin and circulates for a week-plus, giving more consistent IGF-1 elevation and slower tachyphylaxis. Convenience + sustained signal are the win. “With DAC is the one I’m telling you should consider”.
- The no-DAC case (Sawicki, PhD molecular oncology, 2026-06-16, ): “I don’t like [with-DAC]. I’ll be honest.” Two reasons:
- Physiologic-alignment argument: if stacking with Ipamorelin (the standard partner, which should be run roughly 5 nights per week to track the natural overnight GH pulse), the with-DAC’s 8-day half-life produces a constant non-pulsatile signal that misaligns with Ipamorelin’s nightly pulsatile schedule. The stack works cleaner pharmacologically when both peptides match the once-daily-with-clearance pattern that physiologic GH signaling actually uses.
- Stuck-with-it argument: “That long half-life means that if you have side effects or you’re not responding well to it, you’re kind of stuck with it for a week.” No safety off-ramp. With no-DAC’s short half-life, you can adjust within 24 hours.
OHM editorial read: both positions are well-reasoned by serious people; the with-DAC case wins on convenience + signal consistency, the no-DAC case wins on physiologic alignment + safety-off-ramp. Alyve’s CJC-1295/Ipamorelin blend uses no-DAC — which operationally aligns with Sawicki’s preference + the physiologic-alignment argument. Either form is a defensible choice for an informed adult; the choice flows from how heavily you weight convenience vs adjustability.
Pedagogically clean half-life progression across the GHRH-analog catalog — a useful customer-facing framing from Dr. Ashley Froese that maps cleanly onto the Alyve SKU choice between sermorelin, CJC-1295 (DAC vs no-DAC), and tesamorelin:
| Peptide | Half-life | Froese metaphor | Practical signature |
|---|---|---|---|
| Sermorelin | ~10–12 min | “Bright sparkler” | Mimics natural pulses cleanest; DPP-4 degraded fast; gentlest |
| CJC-1295 no-DAC (Mod GRF) | ~30 min | “Mega sparkler” | DPP-4-resistant via amino-acid swaps; daily dosing; still pulsatile |
| CJC-1295 with-DAC | ~6–8 days (PMID 16352683) | “Sparkler glued to a candle” | Albumin-bound, hangs around for ~a week; produces a non-pulsatile constant “growth-hormone bleed” rather than pulses |
| Tesamorelin | ~30 min molecule / ~24 hr effect | “Stable signal” | Full 44-aa GHRH + fatty-acid stability mod (vs the truncated 1-29 analogs above); strongest human RCT base (HIV-lipodystrophy FDA approval) |
The DAC form is a feature-and-risk: it gives the longest exposure but breaks the physiologic pulsatile pattern (the “GH bleed”) — looking more like classical exogenous-GH replacement than peptide-driven pulse mimicking. That’s why the no-DAC daily form is the one that pairs naturally with Ipamorelin in the standard stack: the no-DAC pulse pattern is what the ipamorelin amplifier was designed to layer on.
How can it help me?
The long-acting GHRH analog — a re-engineered version of your own growth-hormone-releasing hormone that resists breakdown and keeps telling your pituitary to make GH. Comes in two forms (with-DAC and no-DAC) that behave very differently. The GHRH half of the famous GH-secretagogue stack.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
What the trial showed: The Teichman RCT reported no serious adverse reactions and called CJC-1295 with-DAC relatively well tolerated, especially in the 30–60 µg/kg range [PMID 16352683].
What users report:
- Flushing and warmth shortly after dosing.
- Water retention — more common with the long-acting with-DAC; some people prefer no-DAC specifically to keep this milder. One practitioner’s fix when GH signaling is pushed too hard: dial the dose back until it resolves.
- Injection-site reactions and occasional headache.
The longer-term considerations, stated plainly: A sustained, days-long GH signal (the with-DAC profile) is not a pattern your body produces naturally, so the sensible move is to keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. One practitioner’s broader safety thesis applies here too: secretagogues preserve pulsatility and your somatostatin brake, which is why he considers them safer than the non-pulsatile flood of exogenous HGH. On cancer, he pushes back on the blanket “GH causes cancer” fear. His own “2004 JCEM ~6,200-patient” cite doesn’t resolve, but the real evidence supports the point: a 2016 meta-analysis (9 studies, 11,191 participants) found GH-replacement therapy in GH-deficient adults was associated with reduced cancer risk (RR 0.69), and the large SAGhE European cohort found no clear excess cancer risk in patients without other major disease. The conservative defaults are still to avoid use with active cancer, uncontrolled diabetes, or significant cardiovascular disease; long-term human safety data for CJC-1295 specifically doesn’t yet exist. Known gaps, named honestly — not alarms.
Regulatory status: CJC-1295 is not FDA-approved; clinical development was not advanced. In October 2023 it was placed on the FDA’s 503A Category 2 bulk-substances list, restricting compounding-pharmacy use and pushing supply to the research-chemical market. WADA prohibits it in sport. Everything sold is research-use-only.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for CJC-1295 are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
This is the protocol the community and practitioners use, from a commonly used practitioner protocol.
No-DAC (the common, daily form):
- Dose: 200 mcg, PM
- Schedule: 5 days on / 2 off
- Cycle: 8 weeks on, then off
- Reconstitution: 10 mg vial + 3 ml bacteriostatic water = 3,333 mcg/ml. A 200 mcg dose = 0.06 ml = 6 units on a U-100 insulin syringe.
With-DAC (the long-acting form): dosed roughly 1–2 mg subcutaneously once or twice weekly — the multi-day half-life is the entire point. One practitioner’s default recommendation is the with-DAC, once-weekly approach for most users; no-DAC “works, you just have to take it every day, and it’s not as effective” in his framing.
Timing: No-DAC is run at night (PM) and often fasted, to ride the natural overnight GH pulse; food near the dose blunts the GH response. With-DAC’s timing matters less because it’s continuously present.
Where experts differ — worth surfacing: The cheat-sheet convention is no-DAC daily. One practitioner prefers with-DAC once-weekly. One nuance to note: in another masterclass one practitioner argues against co-formulating certain peptides in a single vial — yet CJC-1295 + ipamorelin is sold pre-blended industry-wide (and Alyve’s blend is COA-verified at 99.90%). The practical reading: his “don’t mega-dose one constant signal” point is about dosing strategy (don’t blunt your receptors with constant exposure), and the blend is still run in pulses on a cycle, not as a continuous drip. Both the no-DAC daily blend and the with-DAC weekly approach are legitimate paths.
Cycling: Community default is 8-week blocks with breaks; one practitioner’s general rule is to cycle the GH-axis peptides rather than run them indefinitely, to keep receptors responsive.
What should I avoid combining — and what's synergistic?
Stacking — the blend: The dominant use is alongside Ipamorelin in the CJC-1295 / Ipamorelin blend — CJC raises the GHRH baseline, ipamorelin fires the ghrelin-pathway pulse. In the no-DAC blend that’s 250 mcg / 250 mcg per dose, AM/PM, 5-on/2-off, 8 weeks. Alyve sells this pre-blended (in stock, COA 99.90%).
How can I buy this?
Alyve does not currently carry CJC-1295 as a standalone SKU — it’s sold inside the CJC-1295 + Ipamorelin Blend (5 mg / 5 mg, CJC-1295 in the no-DAC form). That blend is in stock at $68.00 (on sale from $78.00) and tested at 99.90% purity by Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity, lot CJI583).
That COA matters more than buyers usually realize. Essentially all peptide raw material flows through a stringency-graded supply chain, and the gray-market tier is batch-to-batch unknown — purity and even identity can vary. A third-party COA at >99%, with identity confirmed by mass spec, is the verified-clean tier. Alyve = the tested-clean option in a market where most product isn’t. Full blend write-up in CJC-1295 / Ipamorelin.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly, as always.)
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
The long-acting GHRH analog — a re-engineered version of your own growth-hormone-releasing hormone that resists breakdown and keeps telling your pituitary to make GH. Comes in two forms (with-DAC and no-DAC) that behave very differently. The GHRH half of the famous GH-secretagogue stack.
| Class | Long-acting GHRH analog (modified GHRH(1-29)) — two forms: with-DAC (drug affinity complex) and no-DAC |
| Mechanism (one-liner) | A durable “make more GH” signal to your pituitary; DAC clips it to blood albumin so it works for days |
| Route | Subcutaneous injection |
| Half-life | With-DAC: 5.8–8.1 days. No-DAC: short (hours) |
| Evidence | Human PK/GH-IGF-1 RCT, with-DAC [PMID 16352683]; preserved pulsatility [PMID 17018654]; mouse proof-of-concept [PMID 16822960]; wide practitioner use |
| Regulatory status | Not FDA-approved. On FDA 503A Category 2 bulk list (2023). WADA-prohibited. |
| Alyve product | Sold inside the in-stock CJC-1295 / Ipamorelin blend (COA 99.90%); no standalone SKU at capture |
| Primary OHM use case | The GHRH baseline-raiser — the “more GH” signal, usually run with Ipamorelin for dual-pathway synergy |
What it is
CJC-1295 is a re-engineered version of the working end of your own GHRH (growth-hormone-releasing hormone). Natural GHRH tells your pituitary to release a pulse of GH — but it’s destroyed within minutes by the enzyme DPP-4. CJC-1295 carries amino-acid swaps that resist that breakdown, so the “make more GH” signal lasts far longer. It comes in two forms, and the difference is the single most important thing to understand about it.
With-DAC carries a Drug Affinity Complex — an albumin-binding hook. Once injected, it latches onto albumin, the most abundant protein in your blood, and becomes effectively invisible to the enzymes and kidneys that would clear it. The result: one injection keeps working for the better part of a week. As one practitioner puts it, the peptide “circulates for over a week, up to two weeks” off a single shot.
No-DAC (also called modified GRF 1-29) skips that hook and clears in hours, so it’s dosed daily. This is the form in most blends, including Alyve’s.
Like Sermorelin, CJC-1295 works upstream — it doesn’t inject GH, it asks your pituitary to make its own, in pulses, with your natural feedback braking intact. That’s the physiologic-restoration approach one practitioner contrasts favorably against exogenous HGH.
How it works
CJC-1295 binds the GHRH receptor on your anterior pituitary. That triggers the standard GHRH cascade — calcium influx, cyclic-AMP spike — and the pituitary releases GH. The engineering is all about durability: native GHRH is shredded by DPP-4 in minutes; CJC-1295’s modifications resist that, and the DAC variant’s albumin-binding extends circulation into days [PMID 16352683].
The most elegant finding from the human work: even with a sustained signal, GH still came out in pulses — your natural rhythm was preserved — and what actually drove IGF-1 up was the raised trough (baseline between pulses), not blown-out peaks. Your body kept its own dimmer switch (somatostatin feedback). That’s why CJC-1295 pairs so naturally with a ghrelin-receptor agonist like Ipamorelin: CJC raises the GHRH-driven baseline, ipamorelin triggers a clean pulse through a separate receptor, and the pituitary — expressing both — puts out more GH together than either alone (see CJC-1295 / Ipamorelin).
On the DAC question, one practitioner is emphatic: native GHRH dies to DPP-4 in minutes; no-DAC lasts a few hours; with-DAC binds albumin and circulates for a week-plus, giving more consistent IGF-1 and slower tachyphylaxis. He steers most users to the DAC form: “with DAC is the one I’m telling you should consider”. He cites a “2013 JCEM” paper for once-weekly with-DAC producing consistent IGF-1 — that specific cite doesn’t resolve, but the real source behind it is Teichman 2005 JCEM (the single-dose ascending-dose RCT showing sustained GH/IGF-1 over 6–11 days), corroborated by Ionescu 2006 on preserved pulsatility.
Where experts read it differently — with-DAC vs no-DAC (added 2026-06-16). Two clearly-articulated expert positions in the KB, presented honestly per umbrella §2 evidence-honesty doctrine so readers can weigh both:
- The with-DAC case (one practitioner): native GHRH dies to DPP-4 in minutes; no-DAC lasts a few hours; with-DAC binds albumin and circulates for a week-plus, giving more consistent IGF-1 elevation and slower tachyphylaxis. Convenience + sustained signal are the win. “With DAC is the one I’m telling you should consider”.
- The no-DAC case (Sawicki, PhD molecular oncology, 2026-06-16, ): “I don’t like [with-DAC]. I’ll be honest.” Two reasons:
- Physiologic-alignment argument: if stacking with Ipamorelin (the standard partner, which should be run roughly 5 nights per week to track the natural overnight GH pulse), the with-DAC’s 8-day half-life produces a constant non-pulsatile signal that misaligns with Ipamorelin’s nightly pulsatile schedule. The stack works cleaner pharmacologically when both peptides match the once-daily-with-clearance pattern that physiologic GH signaling actually uses.
- Stuck-with-it argument: “That long half-life means that if you have side effects or you’re not responding well to it, you’re kind of stuck with it for a week.” No safety off-ramp. With no-DAC’s short half-life, you can adjust within 24 hours.
OHM editorial read: both positions are well-reasoned by serious people; the with-DAC case wins on convenience + signal consistency, the no-DAC case wins on physiologic alignment + safety-off-ramp. Alyve’s CJC-1295/Ipamorelin blend uses no-DAC — which operationally aligns with Sawicki’s preference + the physiologic-alignment argument. Either form is a defensible choice for an informed adult; the choice flows from how heavily you weight convenience vs adjustability.
Pedagogically clean half-life progression across the GHRH-analog catalog — a useful customer-facing framing from Dr. Ashley Froese that maps cleanly onto the Alyve SKU choice between sermorelin, CJC-1295 (DAC vs no-DAC), and tesamorelin:
| Peptide | Half-life | Froese metaphor | Practical signature |
|---|---|---|---|
| Sermorelin | ~10–12 min | “Bright sparkler” | Mimics natural pulses cleanest; DPP-4 degraded fast; gentlest |
| CJC-1295 no-DAC (Mod GRF) | ~30 min | “Mega sparkler” | DPP-4-resistant via amino-acid swaps; daily dosing; still pulsatile |
| CJC-1295 with-DAC | ~6–8 days (PMID 16352683) | “Sparkler glued to a candle” | Albumin-bound, hangs around for ~a week; produces a non-pulsatile constant “growth-hormone bleed” rather than pulses |
| Tesamorelin | ~30 min molecule / ~24 hr effect | “Stable signal” | Full 44-aa GHRH + fatty-acid stability mod (vs the truncated 1-29 analogs above); strongest human RCT base (HIV-lipodystrophy FDA approval) |
The DAC form is a feature-and-risk: it gives the longest exposure but breaks the physiologic pulsatile pattern (the “GH bleed”) — looking more like classical exogenous-GH replacement than peptide-driven pulse mimicking. That’s why the no-DAC daily form is the one that pairs naturally with Ipamorelin in the standard stack: the no-DAC pulse pattern is what the ipamorelin amplifier was designed to layer on.
What the research shows
The full picture, every tier labeled.
The human RCT — Teichman 2005. Randomized, double-blind, placebo-controlled, ascending-dose in healthy adults. A single subcutaneous shot of CJC-1295 with DAC raised mean GH 2-to-10-fold for 6+ days and IGF-1 1.5-to-3-fold for 9–11 days; half-life 5.8–8.1 days; no serious adverse events [PMID 16352683]. This is solid human pharmacology: it proves the molecule does what it’s designed to do — sustainably elevate GH and IGF-1 in people, while remaining well tolerated. What it measured was PK and hormone levels, not body composition — so the lean-mass and fat-loss claims downstream rest on GH/IGF-1 physiology rather than a direct body-comp endpoint in this trial. That’s the honest map.
Preserved pulsatility. A second human study confirmed GH stayed pulsatile during CJC-1295 stimulation and that the IGF-1 rise tracked the raised trough [PMID 17018654]. This is a meaningful safety-and-physiology point — it shows the compound restores a signal rather than flooding the system.
Serum-protein pilot. A small proteomics study (n=11) looked at serum-protein changes after CJC-1295 [PMID 19386527].
Animal proof-of-concept. CJC-1295 normalized growth in GHRH-knockout mice — clean evidence the GHRH-receptor mechanism works as intended in vivo [PMID 16822960].
The no-DAC form — the one in most blends — has the same GHRH-receptor mechanism but no published human PK/efficacy trial of its own; its dosing is community-derived. That’s typical for a research-grade peptide and doesn’t change the mechanism, which is identical at the receptor.
One practitioner extends the GH/IGF-1 story into a wide multi-system benefit map (body composition, mitochondrial function, immune, neuro, cardiovascular, skin) — all downstream of restored GH → IGF-1 signaling. The honest foundation under the body-composition piece is real: Rudman’s landmark 1990 NEJM RCT showed GH replacement in older men improved lean mass, reduced fat, and increased skin/bone density, and Brioche 2014 showed GH replacement prevents sarcopenia with mitochondrial biogenesis in aged rats. Those anchor the GH-axis benefit logic. One practitioner’s specific marquee-journal cites with precise percentages (e.g. “BDNF +45%,” “muscle ATP +35%,” “GH ↑ telomerase,” “−40% HOMA-IR,” “+25% coronary flow”) did not survive PubMed verification — those journal/number attributions are not in the literature and are deliberately omitted here. We keep the qualitative GH-axis benefits tied to the real sources above and drop the fabricated figures.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
This is the protocol the community and practitioners use, from a commonly used practitioner protocol.
No-DAC (the common, daily form):
- Dose: 200 mcg, PM
- Schedule: 5 days on / 2 off
- Cycle: 8 weeks on, then off
- Reconstitution: 10 mg vial + 3 ml bacteriostatic water = 3,333 mcg/ml. A 200 mcg dose = 0.06 ml = 6 units on a U-100 insulin syringe.
With-DAC (the long-acting form): dosed roughly 1–2 mg subcutaneously once or twice weekly — the multi-day half-life is the entire point. One practitioner’s default recommendation is the with-DAC, once-weekly approach for most users; no-DAC “works, you just have to take it every day, and it’s not as effective” in his framing.
Timing: No-DAC is run at night (PM) and often fasted, to ride the natural overnight GH pulse; food near the dose blunts the GH response. With-DAC’s timing matters less because it’s continuously present.
Stacking — the blend: The dominant use is alongside Ipamorelin in the CJC-1295 / Ipamorelin blend — CJC raises the GHRH baseline, ipamorelin fires the ghrelin-pathway pulse. In the no-DAC blend that’s 250 mcg / 250 mcg per dose, AM/PM, 5-on/2-off, 8 weeks. Alyve sells this pre-blended (in stock, COA 99.90%).
Where experts differ — worth surfacing: The cheat-sheet convention is no-DAC daily. One practitioner prefers with-DAC once-weekly. One nuance to note: in another masterclass one practitioner argues against co-formulating certain peptides in a single vial — yet CJC-1295 + ipamorelin is sold pre-blended industry-wide (and Alyve’s blend is COA-verified at 99.90%). The practical reading: his “don’t mega-dose one constant signal” point is about dosing strategy (don’t blunt your receptors with constant exposure), and the blend is still run in pulses on a cycle, not as a continuous drip. Both the no-DAC daily blend and the with-DAC weekly approach are legitimate paths.
Cycling: Community default is 8-week blocks with breaks; one practitioner’s general rule is to cycle the GH-axis peptides rather than run them indefinitely, to keep receptors responsive.
Side effects & management
What the trial showed: The Teichman RCT reported no serious adverse reactions and called CJC-1295 with-DAC relatively well tolerated, especially in the 30–60 µg/kg range [PMID 16352683].
What users report:
- Flushing and warmth shortly after dosing.
- Water retention — more common with the long-acting with-DAC; some people prefer no-DAC specifically to keep this milder. One practitioner’s fix when GH signaling is pushed too hard: dial the dose back until it resolves.
- Injection-site reactions and occasional headache.
The longer-term considerations, stated plainly: A sustained, days-long GH signal (the with-DAC profile) is not a pattern your body produces naturally, so the sensible move is to keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. One practitioner’s broader safety thesis applies here too: secretagogues preserve pulsatility and your somatostatin brake, which is why he considers them safer than the non-pulsatile flood of exogenous HGH. On cancer, he pushes back on the blanket “GH causes cancer” fear. His own “2004 JCEM ~6,200-patient” cite doesn’t resolve, but the real evidence supports the point: a 2016 meta-analysis (9 studies, 11,191 participants) found GH-replacement therapy in GH-deficient adults was associated with reduced cancer risk (RR 0.69), and the large SAGhE European cohort found no clear excess cancer risk in patients without other major disease. The conservative defaults are still to avoid use with active cancer, uncontrolled diabetes, or significant cardiovascular disease; long-term human safety data for CJC-1295 specifically doesn’t yet exist. Known gaps, named honestly — not alarms.
Regulatory status
CJC-1295 is not FDA-approved; clinical development was not advanced. In October 2023 it was placed on the FDA’s 503A Category 2 bulk-substances list, restricting compounding-pharmacy use and pushing supply to the research-chemical market. WADA prohibits it in sport. Everything sold is research-use-only.
The Alyve product
Alyve does not currently carry CJC-1295 as a standalone SKU — it’s sold inside the CJC-1295 + Ipamorelin Blend (5 mg / 5 mg, CJC-1295 in the no-DAC form). That blend is in stock at $68.00 (on sale from $78.00) and tested at 99.90% purity by Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity, lot CJI583).
That COA matters more than buyers usually realize. Essentially all peptide raw material flows through a stringency-graded supply chain, and the gray-market tier is batch-to-batch unknown — purity and even identity can vary. A third-party COA at >99%, with identity confirmed by mass spec, is the verified-clean tier. Alyve = the tested-clean option in a market where most product isn’t. Full blend write-up in CJC-1295 / Ipamorelin.
Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly, as always.)
Sources
- Teichman SL, et al. Prolonged GH/IGF-1 stimulation by CJC-1295 (with DAC) — RCT. J Clin Endocrinol Metab. 2005. : 16352683
- Ionescu M, Frohman LA. Pulsatile GH persists during CJC-1295 stimulation. J Clin Endocrinol Metab. 2006. : 17018654
- Sackmann-Sala L, et al. Serum protein profile changes after CJC-1295. Growth Horm IGF Res. 2009. : 19386527
- Alba M, et al. CJC-1295 normalizes growth in GHRH-knockout mice. Am J Physiol Endocrinol Metab. 2006. : 16822960
- Memdouh S, et al. Detection of GHRH synthetic analogs (DAC vs no-DAC metabolism). Drug Test Anal. 2021. : 34665524
- Rudman D, et al. Effects of human growth hormone in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952
- Brioche T, et al. GH replacement prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
- Li Z, et al. GH replacement therapy reduces cancer risk in GH-deficient adults — meta-analysis (RR 0.69). Oncotarget. 2016. : 27835910 8a. Swerdlow AJ, et al. Cancer risks in patients treated with GH in childhood (SAGhE European cohort). J Clin Endocrinol Metab. 2017. : 28184422
- Video digest — one practitioner CJC-1295/Ipamorelin Masterclass.
- Dosing/reconstitution cheat sheet (one practitioner).
- Alyve COA summary (blend 99.90%, lot CJI583).
- Alyve Peptides — CJC-1295 + Ipamorelin Blend. / https://alyvepeptides.com/product/cjc-1295-ipamorelin-blend/
See also: Ipamorelin, Sermorelin, CJC-1295 / Ipamorelin, Tesamorelin.